NCT06554145 Development and Evaluation of AI Program for Predicting Bacterial Species From Urine Gram Stain Specimens
| NCT ID | NCT06554145 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GramEye |
| Condition | Bacterial Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2023-09-25 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2023-09-25 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to develop an AI that estimates bacterial species from Gram staining images of urine specimens, and to evaluate the accuracy and labor reduction effect of Gram staining Automation system equipped with this AI.
Eligibility Criteria
Inclusion Criteria: * Specimens for which urine culture and urine Gram staining tests were performed for clinical purposes Exclusion Criteria: * Samples for which suspension of use has been requested
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06554145 clinical trial?
This trial is open to participants of all sexes, studying Bacterial Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06554145 currently recruiting?
Yes, NCT06554145 is actively recruiting participants. Contact the research team at tatsuya.yamada@grameye.com for enrollment information.
Where is the NCT06554145 trial being conducted?
This trial is being conducted at Shinjuku-Ku, Japan.
Who is sponsoring the NCT06554145 clinical trial?
NCT06554145 is sponsored by GramEye. The trial plans to enroll 15,000 participants.